These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8993356)

  • 41. Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae.
    Daniels CC; Briles TC; Mirza S; Håkansson AP; Briles DE
    Microb Pathog; 2006 May; 40(5):228-33. PubMed ID: 16540281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mucosal and systemic immunization with a novel attenuated pneumococcal vaccine candidate confer serotype independent protection against Streptococcus pneumoniae in mice.
    Wu K; Yao R; Wang H; Pang D; Liu Y; Xu H; Zhang S; Zhang X; Yin Y
    Vaccine; 2014 Jul; 32(33):4179-88. PubMed ID: 24945468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).
    Briles DE; Tart RC; Swiatlo E; Dillard JP; Smith P; Benton KA; Ralph BA; Brooks-Walter A; Crain MJ; Hollingshead SK; McDaniel LS
    Clin Microbiol Rev; 1998 Oct; 11(4):645-57. PubMed ID: 9767061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection.
    Chen A; Mann B; Gao G; Heath R; King J; Maissoneuve J; Alderson M; Tate A; Hollingshead SK; Tweten RK; Briles DE; Tuomanen EI; Paton JC
    Clin Vaccine Immunol; 2015 Oct; 22(10):1079-89. PubMed ID: 26245351
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP.
    Cao J; Chen D; Xu W; Chen T; Xu S; Luo J; Zhao Q; Liu B; Wang D; Zhang X; Shan Y; Yin Y
    Vaccine; 2007 Jun; 25(27):4996-5005. PubMed ID: 17524530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model.
    Roche H; Håkansson A; Hollingshead SK; Briles DE
    Infect Immun; 2003 Mar; 71(3):1033-41. PubMed ID: 12595413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine.
    Dorosti H; Eslami M; Negahdaripour M; Ghoshoon MB; Gholami A; Heidari R; Dehshahri A; Erfani N; Nezafat N; Ghasemi Y
    J Biomol Struct Dyn; 2019 Aug; 37(13):3524-3535. PubMed ID: 30634893
    [No Abstract]   [Full Text] [Related]  

  • 48. Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae.
    Seong SY; Cho NH; Kwon IC; Jeong SY
    Infect Immun; 1999 Jul; 67(7):3587-92. PubMed ID: 10377143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring.
    Kono M; Hotomi M; Hollingshead SK; Briles DE; Yamanaka N
    PLoS One; 2011; 6(10):e27102. PubMed ID: 22073127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pneumococcal surface protein A and new approaches for pneumococcal vaccine development].
    Vorob'ev DS; Semenova IB
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (6):107-13. PubMed ID: 22308742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of SP1683 as a pneumococcal protein that is protective against nasopharyngeal colonization.
    Moens L; Hermand P; Wellens T; Wuyts G; Derua R; Waelkens E; Ysebaert C; Godfroid F; Bossuyt X
    Hum Vaccin Immunother; 2018 May; 14(5):1234-1242. PubMed ID: 29400602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel Immunoprotective Proteins of Streptococcus pneumoniae Identified by Opsonophagocytosis Killing Screen.
    Wang Y; Wen Z; Pan X; Briles DE; He Y; Zhang JR
    Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29891544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA).
    Katsurahara T; Hotomi M; Yamauchi K; Billal DS; Yamanaka N
    J Infect Chemother; 2008 Dec; 14(6):393-8. PubMed ID: 19089550
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260.
    McDaniel LS; Ralph BA; McDaniel DO; Briles DE
    Microb Pathog; 1994 Nov; 17(5):323-37. PubMed ID: 7723659
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pneumococcal pep27 mutant immunization stimulates cytokine secretion and confers long-term immunity with a wide range of protection, including against non-typeable strains.
    Kim GL; Choi SY; Seon SH; Lee S; Park SS; Song JY; Briles DE; Rhee DK
    Vaccine; 2016 Dec; 34(51):6481-6492. PubMed ID: 27865564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
    Vadesilho CF; Ferreira DM; Moreno AT; Chavez-Olortegui C; Machado de Avila RA; Oliveira ML; Ho PL; Miyaji EN
    Microb Pathog; 2012; 53(5-6):243-9. PubMed ID: 22981893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenic protein contaminants in pneumococcal vaccines.
    Yu J; Briles DE; Englund JA; Hollingshead SK; Glezen WP; Nahm MH
    J Infect Dis; 2003 Mar; 187(6):1019-23. PubMed ID: 12660950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.
    Tostes RO; Rodrigues TC; da Silva JB; Schanoski AS; Oliveira ML; Miyaji EN
    PLoS One; 2017; 12(1):e0170157. PubMed ID: 28103277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. C-Terminal Clostridium perfringens Enterotoxin-Mediated Antigen Delivery for Nasal Pneumococcal Vaccine.
    Suzuki H; Watari A; Hashimoto E; Yonemitsu M; Kiyono H; Yagi K; Kondoh M; Kunisawa J
    PLoS One; 2015; 10(5):e0126352. PubMed ID: 26018248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice.
    Lima FA; Miyaji EN; Quintilio W; Raw I; Ho PL; Oliveira ML
    Vaccine; 2013 May; 31(20):2465-70. PubMed ID: 23541622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.